Showing 2 of 2 recruiting trials for “T-cell non-Hodgkin lymphoma”
TmCD19-IL18 in CD19+ Cancers
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
👨⚕️ Yuqin Song, MD, PhD, Peking University Cancer Hospital & Institute📍 1 site📅 Started Jun 2020View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →